Measles roars back in the US, topping 1,000 cases
The United States' measles outbreak has surpassed 1,000 confirmed cases with three deaths so far, state and local data showed Friday, marking a stark resurgence of a vaccine-preventable disease that the nation once declared eliminated.
The surge comes as Health Secretary Robert F. Kennedy Jr. continues to undermine confidence in the measles, mumps, and rubella (MMR) vaccine -- a highly effective shot he has falsely claimed is dangerous and contains fetal debris.
An AFP tally showed there have been at least 1,012 cases since the start of the year, with Texas accounting for more than 70 percent.
A vaccine-skeptical Mennonite Christian community straddling the Texas-New Mexico border has been hit particularly hard.
A federal database maintained by the Centers for Disease Control and Prevention (CDC) has lagged behind state and county reporting, as the globally renowned health agency faces deep workforce and budget cuts under President Donald Trump's administration.
North Dakota is the latest state to report an outbreak, with nine cases so far. Around 180 school students have been forced to quarantine at home, according to the North Dakota Monitor.
"This is a virus that's the most contagious infectious disease of mankind and it's now spreading like wildfire," Paul Offit a pediatrician and vaccine expert at the Children's Hospital of Philadelphia told AFP.
He warned the true case count could be far higher, as people shy away from seeking medical attention. "Those three deaths equal the total number of deaths from measles in the last 25 years in this country."
The fatalities so far include two young girls in Texas and an adult in New Mexico, all unvaccinated -- making it the deadliest US measles outbreak in decades.
It is also the highest number of cases since 2019, when outbreaks in Orthodox Jewish communities in New York and New Jersey resulted in 1,274 infections but no deaths.
Nationwide immunization rates have been dropping in the United States, fueled by misinformation about vaccines, particularly in the wake of the Covid-19 pandemic.
The CDC recommends a 95 percent vaccination rate to maintain herd immunity.
However, measles vaccine coverage among kindergartners has dropped from 95.2 percent in the 2019-2020 school year to 92.7 percent in 2023-2024.
Measles is a highly contagious respiratory virus spread through droplets when an infected person coughs, sneezes or simply breathes.
Known for its characteristic rash, it poses a serious risk to unvaccinated individuals, including infants under 12 months who are not ordinarily eligible for vaccination, and those with weakened immune systems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
6 hours ago
- Express Tribune
CDC, commissioner reinforce polio eradication commitment
A delegation from the US Centers for Disease Control and Prevention (CDC) Polio Branch discussed sustaining momentum toward eradication goals, including continued CDC technical assistance and capacity building of health department staff. The critical role of NSTOP officers in supporting District Emergency Operations Centers (DEOCs) was highlighted as a key element of the response structure. The CDC Polio Branch delegation was led by Dr Richard Franka, and met with Commissioner Karachi Syed Hasan Naqvi to discuss sustained efforts in the fight against polio. During the meeting, the epidemiological significance of Karachi as a core polio reservoir was underscored - owing to its large, heterogeneous population and continuous population movement, which present complex challenges for eradication efforts. Both parties emphasised the importance of maintaining high-quality surveillance and vaccination coverage to interrupt transmission. The active role of the deputy commissioners across Karachi was also acknowledged, particularly their continued leadership and on-ground coordination in supporting the polio eradication cause. Their commitment to ensuring effective implementation of polio campaigns and rapid response efforts have been instrumental in driving progress. Commissioner Karachi, Syed Hasan Naqvi, reiterated the need to maintain NSTOP's support in core reservoir districts and stressed the importance of enhancing the capacity of frontline workers (FLWs) at the national level. He advocated for providing FLWs with a conducive working environment and proposed organising appreciation events to recognise their dedication and hard work - an essential step to boost morale and sustain motivation across the frontline workforce. As a token of appreciation, souvenirs were presented to the CDC delegation in recognition of their ongoing support.
Business Recorder
10 hours ago
- Business Recorder
Looser gun laws tied to thousands more US child shooting deaths
WASHINGTON: US states that loosened their gun laws following a landmark court ruling saw thousands more childhood firearm deaths than they otherwise would have -- the vast majority homicides and suicides -- according to a study published Monday. Jeremy Faust, an emergency physician at Brigham and Women's Hospital in Boston and lead author of the paper in JAMA Pediatrics, told AFP he was drawn to the topic as a father wondering whether today's world is safer for children than when he was growing up. "Mortality from car accidents has fallen dramatically, but at the same time, firearm mortality rose and replaced car accidents as the leading cause of death in children over the age of one," he said -- a trend unique among peer nations. Washington Post reveals US weapons used by terrorists in attacks To probe this shift, Faust and his colleagues analyzed state-level data before and after McDonald v Chicago, the 2010 Supreme Court decision that extended the Second Amendment to state and local governments. The ruling sparked a wave of legislation, some tightening gun laws but much of it loosening them. The team grouped states into three categories -- most permissive, permissive, and strict -- and used Centers for Disease Control data on firearm deaths among children aged 0-17. They ran an "excess mortality analysis," comparing actual deaths from 2011 to 2023 against projections based on prior trends from 1999 to 2010 and population growth. The results were stark: more than 7,400 excess pediatric firearm deaths in states that loosened gun laws -- including over 6,000 in the most permissive group of states. By contrast, the eight strictest states overall saw no excess deaths. The model predicted 4,267 fatalities, while 4,212 were recorded -- a near-match that bolstered confidence in the analysis. "The biggest thing people always want to know is, what's the intent behind these?" said Faust. "And I think what surprises most people is that accidents are a very small number of these deaths -- it's mostly homicide and suicide." While the study showed strong associations, it cannot prove causation -- a key limitation. But in a test of whether broader increases in violence might explain the trend, rather than changes to the law, the team analyzed non-firearm homicides and suicides and found no similar rise, a result that makes the findings "pretty compelling," said Faust. Black children saw the steepest increases. While the reasons are unclear, the authors speculated that disparities in safe firearm storage could play a role. There were some exceptions. Deaths rose in Illinois and Connecticut despite tighter laws -- though in the latter case, the spike was entirely attributable to the 2012 Sandy Hook mass shooting at an elementary school. "Big picture, we have a major problem in this country," said Faust. "But we also have a handful of states that are resisting these increases and, in fact, turning the other direction."
Business Recorder
3 days ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
